Statins personalized

Med Clin North Am. 2012 Jan;96(1):123-39. doi: 10.1016/j.mcna.2011.11.004. Epub 2012 Jan 31.

Abstract

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor medications, commonly referred to as statins, are among the most widely prescribed medications. Variation in individual response to statins concerning low-density lipoprotein cholesterol reduction, clinical event benefit, and side effects has been observed. Some of this variability is attributed to demographic and environmental issues, chief of which is compliance. A large portion of the individual response to statin therapy is attributed to single nucleotide polymorphisms that have recently been elucidated, several of which seem to have clinical utility.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cholesterol, LDL / metabolism
  • Drug Resistance / genetics*
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / metabolism
  • Forecasting
  • Gene-Environment Interaction
  • Humans
  • Hydroxymethylglutaryl CoA Reductases / genetics*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / pharmacokinetics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Lipid Metabolism / genetics*
  • Patient Compliance
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide / drug effects
  • Precision Medicine* / methods
  • Precision Medicine* / trends

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hydroxymethylglutaryl CoA Reductases